<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Cao et al. reported on three patients with severe COVID-19 who received high-dose IVIG at a dose of 0.3–0.5 g/kg/day for 5 days [
 <xref ref-type="bibr" rid="CR83">83</xref>]. All patients clinically improved shortly after the administration, normal body temperature was achieved in 1–2 days and respiratory rate improved in 3–5 days. These results are in line with a retrospective study of 58 severe to critically ill COVID-19 patients [
 <xref ref-type="bibr" rid="CR84">84</xref>]. The study reported a statistically significant difference in 28-day mortality between patients who received IVIG adjuvant therapy for COVID-19 pneumonia within 48 h of admission compared with those who received IVIG after 48 h (23.3% vs. 57.1%, 
 <italic>p</italic> = 0.009). Thus, as with convalescent plasma, earlier initiation of therapy is encouraged. In spite of this, a different retrospective study of 325 severe or critical COVID-19 patients reported no difference in 28-day or 60-day mortality between patients who were treated with IVIG and those who were not (
 <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2.full.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2.full.pdf</ext-link>).
</p>
